Your browser doesn't support javascript.
loading
Adverse events associated with encorafenib plus binimetinib in the COLUMBUS study: incidence, course and management.
Gogas, Helen J; Flaherty, Keith T; Dummer, Reinhard; Ascierto, Paolo A; Arance, Ana; Mandala, Mario; Liszkay, Gabriella; Garbe, Claus; Schadendorf, Dirk; Krajsova, Ivana; Gutzmer, Ralf; Sileni, Vanna Chiarion; Dutriaux, Caroline; de Groot, Jan Willem B; Yamazaki, Naoya; Loquai, Carmen; Gollerkeri, Ashwin; Pickard, Michael D; Robert, Caroline.
Afiliação
  • Gogas HJ; Department of Internal Medicine, National and Kapodistrian University of Athens, Laikon Hospital, Athens, Greece. Electronic address: helgogas@gmail.com.
  • Flaherty KT; Cancer Center, Massachusetts General Hospital, Boston, MA, USA.
  • Dummer R; Department of Dermatology, University Hospital Zürich Skin Cancer Center and University Zürich, Zürich, Switzerland.
  • Ascierto PA; Melanoma Unit, Cancer Immunotherapy and Innovative Therapies, Istituto Nazionale Tumori IRCCS Fondazione Pascale, Naples, Italy.
  • Arance A; Department of Medical Oncology, Hospital Clinic of Barcelona, Barcelona, Spain.
  • Mandala M; Department of Oncology and Haematology, Papa Giovanni XXIII Cancer Center Hospital, Bergamo, Italy.
  • Liszkay G; Department of Dermatology, National Institute of Oncology, Budapest, Hungary.
  • Garbe C; Department of Dermatology, University Hospital Tuebingen, Tuebingen, Germany.
  • Schadendorf D; Department of Dermatology, University Hospital Essen, Essen, Germany, and German Cancer Consortium, Heidelberg, Germany.
  • Krajsova I; Department of Dermato-oncology, University Hospital Prague and Charles University First Medical Faculty, Prague, Czech Republic.
  • Gutzmer R; Department of Dermatology and Allergy, Skin Cancer Center Hannover, Hannover Medical School, Hannover, Germany.
  • Sileni VC; Melanoma Cancer Unit, Oncology Institute of Veneto IRCCS, Padua, Italy.
  • Dutriaux C; Department of Oncologic Dermatology, Centre Hospitalier Universitaire de Bordeaux, Hôpital Saint-André, Bordeaux, France.
  • de Groot JWB; Department of Medical Oncology, Isala, Zwolle, Netherlands.
  • Yamazaki N; Department of Dermatologic Oncology, National Cancer Center Hospital, Tokyo, Japan.
  • Loquai C; Department of Dermatology, University Medical Center Mainz, Mainz, Germany.
  • Gollerkeri A; Array BioPharma Inc., Boulder, CO, USA.
  • Pickard MD; Array BioPharma Inc., Boulder, CO, USA.
  • Robert C; Service of Dermatology, Department of Medicine and Paris-Sud University, Gustave Roussy, Villejuif, France.
Eur J Cancer ; 119: 97-106, 2019 09.
Article em En | MEDLINE | ID: mdl-31437754
Assuntos
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias Cutâneas / Protocolos de Quimioterapia Combinada Antineoplásica / Proteínas Quinases Ativadas por Mitógeno / Proteínas Proto-Oncogênicas B-raf / Inibidores de Proteínas Quinases / Melanoma Tipo de estudo: Clinical_trials / Incidence_studies / Prognostic_studies / Risk_factors_studies Idioma: En Revista: Eur J Cancer Ano de publicação: 2019 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias Cutâneas / Protocolos de Quimioterapia Combinada Antineoplásica / Proteínas Quinases Ativadas por Mitógeno / Proteínas Proto-Oncogênicas B-raf / Inibidores de Proteínas Quinases / Melanoma Tipo de estudo: Clinical_trials / Incidence_studies / Prognostic_studies / Risk_factors_studies Idioma: En Revista: Eur J Cancer Ano de publicação: 2019 Tipo de documento: Article